33 results about "Fibrosarcoma" patented technology

The invention discloses an amino acid positron emission tomography (PET) imaging agent, and a preparation method and application thereof. The imaging agent belongs to the field of N-substituted positron nuclide labeled glutamic acid compound and has a structure as shown in the specification; and the L*represents -11CH3, CH2CH218F, and -COCH (18F) CH3. The novel imaging agent N-(2-18F-fluoropropionyl)-glutamic acid shows good tumor PET imaging sensitivity and specificity, has high uptake on tumor (such as S180 fibrosarcoma), and no obvious uptake on other tissues and organs (except for bladder) in the body, and indicates high tumor to background ratio. In vitro-in vivo experiments show that N-(2 - 18F -fluoropropionyl)-glutamic acid is stable in vitro and in vivo and shows good pharmacokinetic properties.

Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.

The invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to α2β1 integrin.

The establishing process of mesoblastic nephroma animal model includes the following steps: primary culture of embryo muscle cell of mammal; subculture after the cell grows to fuse; extracorporeal culture for 3-8 months to obtain cloning cell in the culture and eternal tumor cell line; passaging for several times after malignant cell transformation to obtain monoclinic cell strain via monoclonal culture; nude mouse hypodermic transplantation of the monoclinic cell strain; identifying the tumor cell strain by means of immunocytochemistry method or molecular biological method; transplanting the obtained fibrosarcoma cell strain to nude mouse renal diolame to obtain the mesoblastic nephroma animal model. The mesoblastic nephroma animal model provides the research of mesoblastic nephroma pathogenesis and treatment with technological platform.

Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.

Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid σ1 protein and expresses a mutated reoviral outer capsid σ3 protein.

The invention belongs to the field of biological medicine, and relates to basic fibroblast growth factor activated fibroblast as well as a preparation method and an application thereof. The invention aims at solving the technical problem for providing a new selection for tumour treatment. The invention provides a tumour universal type fibroblast vaccine, and a main active component of the vaccine is inactivated basic fibroblast growth factor activated fibroblast. The invention aims at providing the novel cell vaccine for researching and developing tumour fibroblast; and the vaccine can inhibit a plurality of tumours, and is used as a universal antineoplastic vaccine for control of colorectal carcinoma, lung cancer, fibrosarcoma and the like.

The present invention relates to peptides that inhibit the excessive production and / or accumulation of an extracellular matrix in an organ or tissue. The peptides of the invention have the general formula sequence Xa-Leu-Gln-Gly-Xb (SEQ ID NO: 1) wherein Xa is selected from the group consisting of Pro-Gly, Gly and Ac-Gly and Xb is selected from the group consisting of Glu and Glu-NH2, which peptides are capable of inhibiting excessive production and excessive accumulation of extracellular matrix in organs or tissues in the form of linear peptides and cyclic peptides. In particular, the peptides disclosed herein are useful for the treatment of fibrotic disorders characterized by excessive accumulation of extracellular matrix, such as liver fibrosis, cirrhosis, pulmonary fibrosis, chronic respiratory failure, cardiac fibrosis, ischemic heart disease, heart failure, diabetic nephropathy, glomerulonephritis, myelofibrosis, and various types of cancers, such as liver fibrosis, liver cirrhosis, pulmonary fibrosis, chronic respiratory failure, cardiac fibrosis, ischemic heart disease, heart failure, diabetic nephropathy, glomerulonephritis, myelofibrosis, and the like. Such as breast cancer, uterine cancer, prostate cancer, pancreatic cancer, colon cancer, skin cancer, blood cell cancer, central nervous system cancer, fibromyoma, fibroma, fibroadenoma and fibrosarcoma.

The invention discloses an amino acid positron emission tomography (PET) imaging agent, and a preparation method and application thereof. The imaging agent belongs to the field of N-substituted positron nuclide labeled glutamic acid compound and has a structure as shown in the specification; and the L*represents -11CH3, CH2CH218F, and -COCH (18F) CH3. The novel imaging agent N-(2-18F-fluoropropionyl)-glutamic acid shows good tumor PET imaging sensitivity and specificity, has high uptake on tumor (such as S180 fibrosarcoma), and no obvious uptake on other tissues and organs (except for bladder) in the body, and indicates high tumor to background ratio. In vitro-in vivo experiments show that N-(2 - 18F -fluoropropionyl)-glutamic acid is stable in vitro and in vivo and shows good pharmacokinetic properties.

The present invention relates to the use of a nucleic acid that comprises a sequence encoding an APOBEC3A protein, in preventing or treating a tumor in a patient.

The invention provides an extracting method of a plant composite containing mycelia of cultured cordyceps sinensis. The plant composite is prepared from the raw material herbs of 100 g of mycelia of cultured cordyceps sinensis, 60 g of gentiana apiata, 80 g of salvia chinensis and 160 g of Chinese pennisetum. The plant composite is prepared by the adoption of the microwave extracting method, in this way, the content is greatly increased, and the usage amount is reduced. The invention further provides an application of the plant composite containing the mycelia of cultured cordyceps sinensis in preparation of medicine for restraining C57BL / 6 mice fibrosarcoma S180 cell proliferation.

The invention reveals that the V-Maf bird myofascia fibrosarcoma cancer gene homolog G (MAFG) is a regulation target of cholesterol homeostasis, and the MAFG and a regulator thereof can be used as a new way for developing drugs for high cholesterol related diseases (such as hypercholesterolemia and atherosclerosis) or low cholesterol related diseases.

The invention discloses an application of miltipolone or pharmaceutically acceptable salts thereof in the preparation of medicines for preventing or curing diseases related to Fe2+. A cancer cell inhibiting effect of the medicines prepared by the miltipolone or the pharmaceutically acceptable salts thereof realizes the purpose of anticancer through inhibiting cancer cell proliferation ; and particularly, the invention provides new choices of the medicines for curing or preventing human lung cancer, human liver cancer, human cervical carcinoma, human breast carcinoma, leukocythemia, fibrosarcoma, or gastric cancer.

The invention provides new application of valeriana jatamansi jones total flavonoids, in particular application in preparing a medicament for treating liver cancer or fibrosarcoma. The invention also provides a medicinal composition for treating liver cancer or fibrosarcoma. The valeriana jatamansi jones total flavonoids have remarkable inhibiting effect on the growth of tumors in mice inoculatedwith liver cancer H22 and fibrosarcoma S180 so as to show that the valeriana jatamansi jones total flavonoids have obvious effect of resisting the liver cancer and the fibrosarcoma and provide a new medicament selection for clinic.

The present invention relates to a hydroxyapatite and / or tricalcium phosphate powder characterized in that it has undergone at least one sintering step at a temperature between 400° C. and 600° C. The invention also relates to a process for preparing such a powder, and to a composition comprising such a powder for use as an anti-tumour auto-vaccine and particularly in the treatment of the following pathological conditions: osteosarcoma, B or T lymphoma, mammary tumour, melanoma, haemangiosarcoma, mastocytoma, fibrosarcoma, brain tumours and schwannoma in a subject. The present invention also covers a drug combination comprising the composition of the invention and at least one second therapeutic agent, preferably an anti-tumour agent and / or a radiotherapeutic agent.